Imagine a digital hub that gathers everything about a patient's health—from doctor reports and wearable watch data to how the patient actually feels every day. Instead of this information being scattered in different folders, it's all synced in one place. This makes it much easier for scientists to see if a new medicine is actually working in real life.
Developing treatments for rare diseases is slowed by fragmented data and a lack of insight into patient preferences. This makes recruiting for clinical trials difficult and regulatory approval uncertain.
An omni data platform called the Interactium, including a patient interface for data control, a wearable device infrastructure, and a toolkit for patient organizations.
If you are a drug developer dealing with limited patient numbers for clinical trials — this project developed the Interactium platform that uses real-world data to facilitate successful clinical trials and support regulatory decision-making.
If you are a wearable tech company dealing with fragmented data integration — this project developed an architecture for wearable infrastructure that aligns device data with clinical registries to improve patient outcomes.
If you are a clinic dealing with inconsistent care standards — this project developed tools to create standards of care guidelines using patient-reported data to monitor and improve patient care.
Based on available project data, there is no specific pricing model mentioned; however, the project received an EU contribution of EUR 2,687,970 for development.
Yes, the project aims to provide shared learning to scale-up similar systems across all rare diseases and suggests it is equally relevant to common diseases like diabetes.
Based on available project data, the project focuses on FAIR data principles and appropriate consents, but specific licensing terms for the software are not detailed.
The platform is specifically designed to provide patient data that supports regulatory decision-making and aligns with the needs of regulators.
It integrates data from patient registries, patient-reported outcome measures, and Internet of Things devices into a single omni data platform.
The consortium is well-balanced for commercial translation, consisting of 12 partners across 6 countries. With a 25% industry ratio (3 industrial partners) and 4 SMEs, there is a strong bridge between academic research and market application. The leadership by a patient organization ensures the end-user needs are integrated into the technical development.
Contact Parent Project Aps in Italy
Contact us to explore licensing the Interactium architecture for your therapeutic area.
